Indivi Secures CHF 15 Million to Advance Biomarker Discovery in Alzheimer’s and Neuroscience Drug Development
Indivi, an independent TechBio company pioneering precision medicine solutions for neuroscience, today announced the successful closing of a CHF 15 million investment round led by Ava Investors. This strategic financing will accelerate Indivi’s mission to validate and deploy innovative biomarker technologies aimed at transforming the early phases of neuroscience drug development, with an initial focus on Alzheimer’s disease (AD).
The newly secured funding represents a significant milestone for Indivi as it expands efforts to bring cutting-edge precision tools into the complex and high-risk field of neurodegenerative research. By leveraging advanced data analytics and deep phenotyping platforms, Indivi aims to enhance the detection of early treatment responses and improve the predictability of clinical outcomes in Alzheimer’s and related conditions.
Addressing One of Medicine’s Greatest Challenges
The field of neurodegeneration remains one of the toughest challenges in medicine,” said Dr. Shibeshih Belachew, Chief Medical Officer at Indivi. “We are thrilled to bolster our efforts to augment the success rate of promising assets to reach the proof-of-concept stage, where conventional endpoints often lack the sensitivity needed to detect early treatment effects.”
Current Alzheimer’s research is hampered by limitations in traditional clinical trial endpoints, which struggle to capture subtle but meaningful treatment benefits during early-stage disease progression. Indivi’s technology is designed to bridge this critical gap by identifying functional and electrophysiological biomarkers that are more sensitive and reflective of neurobiological changes, thereby improving early detection of therapeutic efficacy.
Pioneering a New Generation of Biomarkers
The capital infusion will allow Indivi to launch a proof-of-concept clinical trial in 2026, focused on identifying and validating functional and electrophysiological biomarkers that demonstrate superior pharmacodynamic responses to β-amyloid-depleting therapies. The company’s approach integrates neuroscience, digital health, and computational biology to create a multidimensional understanding of brain function and drug response.
If successful, the trial could establish a new generation of responsive biomarkers capable of revealing early and definitive signs of treatment benefit in Alzheimer’s disease. These biomarkers could play a transformative role in optimizing trial design, accelerating go/no-go decisions, and ultimately increasing the success rate of novel therapies entering clinical testing.
Transforming Neuroscience Through Deep Phenotyping
Our mission is to make measurable what is not so, by capturing early treatment benefits on complex neurological disease traits through accessible deep phenotyping software technologies,” said Guilhem Dupont, Chief Executive Officer of Indivi. By combining computational modeling with electrophysiological insights, we aim to provide drug developers with a precise, data-driven understanding of treatment response in the brain.”
Indivi’s proprietary software platform applies deep phenotyping, a method that quantifies subtle, multidimensional patterns in patient physiology and behavior using advanced analytics. This approach allows the company to detect early, quantifiable changes in neurological function that traditional methods may overlook, helping to reduce uncertainty in clinical development and shorten timelines to proof of concept.
Driving Precision Medicine in Neuroscience
The investment led by Ava Investors underscores growing confidence in Indivi’s scientific vision and its potential to reshape the landscape of neuroscience drug development. As pharmaceutical and biotech companies increasingly seek precision tools to de-risk clinical trials, Indivi’s biomarker-driven approach aligns with the industry’s move toward personalized, data-centric drug discovery.
Indivi’s work contributes to a broader shift in neuroscience — from symptom-based assessment to objective, measurable biological endpoints. By improving the ability to detect treatment effects earlier, Indivi aims to accelerate the development of disease-modifying therapies and bring new hope to patients and families affected by Alzheimer’s disease.
About Indivi
Indivi is an ISO 13485 and ISO 27001-certified TechBio company headquartered in Basel (Switzerland) and developing future-proof functional biomarkers derived from DHT tools measuring key disability concepts of importance for drug development trials in neuroscience therapeutic areas, e.g. multiple sclerosis, Parkinson’s disease and other alpha-synucleinopathies, Alzheimer’s disease and related dementias, muscular dystrophies and neuromuscular disorders.
Indivi and Clouds of Care recently established a unified R&D framework for multimodal deep phenotyping, combining biological (electrophysiology) and functional (sensor-derived assessments of cognitive and motor behavior) measures to deliver earlier definitive Proof-of-Biology (PoB) and Proof-of-Concept (PoC) signals in neuroscience drug development.
Indivi provides a technology-integrated value proposition de-risking early clinical development, by increasing the signal-to-noise ratio of PoB-PoC endpoints, thereby enhancing the probability of technical and regulatory success, potentially improving the risk-adjusted net present value, and accelerating time-to-market for biopharmaceutical partners.
source link: https://www.businesswire.com
